CV Sciences Reports Q1 2025 Financial Results

The latest update is out from CV Sciences ( (CVSI) ).

On May 14, 2025, CV Sciences announced its financial results for the first quarter of 2025, reporting a revenue of $3.6 million, a decrease from the previous year due to lower sales volume. Despite this, the company achieved an operating income of $11,000, an improvement from a loss in the previous year, attributed to reduced operating expenses and a reversal of accrued payroll taxes. The company also launched a new plant-based product line, Lunar Fox, targeting the growing vegan food market, marking a significant step in its transition to a global health and wellness company.

Spark’s Take on CVSI Stock

According to Spark, TipRanks’ AI Analyst, CVSI is a Underperform.

CV Sciences exhibits significant financial and liquidity challenges, reflected in its low financial performance score. While strategic initiatives from the earnings call show potential for future growth, current technical and valuation metrics are weak. Overall, the stock’s prospects are constrained by its financial instability and market conditions.

To see Spark’s full report on CVSI stock, click here.

More about CV Sciences

CV Sciences, Inc. is a consumer wellness company specializing in nutraceuticals and plant-based foods. The company offers hemp extracts and other science-backed natural ingredients and products, with their +PlusCBD branded products being the top-selling hemp-extract brand in the natural products market. CV Sciences also produces cannabinoid-free supplements and plant-based food products under various brands, catering to vegan, gluten-free, and flexitarian consumers. The company operates in the U.S. and Europe, with primary offices in San Diego, California, Grand Junction, Colorado, and Warsaw, Poland.

Average Trading Volume: 207,142

Technical Sentiment Signal: Sell

Current Market Cap: $5.44M

For a thorough assessment of CVSI stock, go to TipRanks’ Stock Analysis page.